SCA
KPRX icon

Sassicaia Capital Advisers’s Kiora Pharmaceuticals KPRX Stock Holding History

Sassicaia Capital Advisers’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-69
Closed -$56K – 31
2021
Q3 		$56K Buy
+69
New +$58.6K 0.16% 37

Other funds holding KPRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Sassicaia Capital Advisers's KPRX Position: Q4 2021 in Review

Sassicaia Capital Advisers sold out of Kiora Pharmaceuticals (KPRX) in Q4 2021, closing a stake of 69 shares — an estimated $56K sold.

Sassicaia Capital Advisers first reported a position in KPRX in Q3 2021 and held it in 1 quarter. The position peaked at $56K in Q3 2021. 11 funds tracked by Wall St. Rank hold KPRX as of Q4 2021.

  • Sassicaia Capital Advisers reported no remaining Kiora Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 69 Kiora Pharmaceuticals shares in Q4 2021, an estimated $56K.
  • Sassicaia Capital Advisers first reported a position in Kiora Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Sassicaia Capital Advisers's Kiora Pharmaceuticals position peaked at $56K in Q3 2021.
  • 11 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q4 2021.

Based on Sassicaia Capital Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.